Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[ 18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 10, 2009, Pages 1565-1573

  Postema, Ernst J ^a   McEwan, Alexander J B ^a   Riauka, Terence A ^a   Kumar, Piyush ^a   Richmond, Dacia A ^a   Abrams, Douglas N ^a   Wiebe, Leonard I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

18F FAZA; Hypoxia; Oncology; Positron emission tomography

Indexed keywords

1 ALPHA DEXTRO (5 DEOXY 5 FLUOROARABINOFURANOSYL) 2 NITROIMIDAZOLE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ASTROCYTOMA; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DISTRIBUTION; DRUG SAFETY; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HODGKIN DISEASE; HUMAN; HYPOXIA; IMAGE ANALYSIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORINE RADIOISOTOPES; GLIOMA; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; YOUNG ADULT;

EID: 70350532485     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1154-5     Document Type: Article

References (28)

1. M Höckel P Vaupel 2001 Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 266 276 10.1093/jnci/93.4.266 11181773 10.1093/jnci/93.4.266
2. M Höckel C Knoop K Schlenger B Vorndran E Baussmann M Mitze, et al. 1993 Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix Radiother Oncol 26 45 50 10.1016/0167-8140(93)90025-4 8438086 10.1016/0167-8140(93)90025-4
3. DM Brizel GS Sibley LR Prosnitz RL Scher MW Dewhirst 1997 Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int J Radiat Oncol Biol Phys 38 285 289 10.1016/S0360-3016(97)00101-6 9226314 1:STN:280:DyaK2szmvFyksQ%3D%3D (Pubitemid 27318643)
4. M Nordsmark M Hoyer J Keller OS Nielsen OM Jensen J Overgaard 1996 The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas Int J Radiat Oncol Biol Phys 35 701 8 10.1016/0360-3016(96) 00132-0 8690636 1:STN:280:DyaK28zgsFWmtA%3D%3D (Pubitemid 26251125)
5. ST Lee AM Scott 2007 Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole Semin Nucl Med 37 451 461 10.1053/j.semnuclmed.2007.07. 001 17920352 10.1053/j.semnuclmed.2007.07.001 (Pubitemid 47498258)
6. RC Urtasun MB Parliament AJ McEwan JR Mercer RH Mannan LI Wiebe, et al. 1996 Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside Br J Cancer Suppl 27 S209 S212 8763882 1:STN:280:DyaK283osFWqtQ%3D%3D
7. AL Grosu M Souvatzoglou B Röper M Dobritz N Wiedenmann V Jacob, et al. 2007 Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 541 551 10.1016/j.ijrobp. 2007.05.079 17869667 1:CAS:528:DC%2BD2sXhtVeqs7jP
8. JD Chapman 1991 Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies Radiother Oncol 20 Suppl 1 13 19 10.1016/0167-8140(91)90181-F 2020762 10.1016/0167-8140(91)90181-F
9. LI Wiebe D Stypinski 1996 Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues Q J Nucl Med 40 270 284 8961804 1:STN:280: DyaK2s7itFWgtQ%3D%3D
10. L Bentzen S Keiding MR Horsman L Falborg SB Hansen J Overgaard 2000 Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography - a study evaluating [18F]fluoro-2-deoxy-D-glucose Acta Oncol 39 629 637 10.1080/028418600750013320 11093372 10.1080/028418600750013320 1:STN:280:DC%2BD3M%2Fkt12ltg%3D%3D
11. P Kumar D Stypinski H Xia AJB McEwan HJ Machulla LI Wiebe 1999 Fluoroazomycin arabinoside (FAZA): synthesis, 2H and 3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia J Label Comp Radiopharmaceuticals 42 3 16 10.1002/(SICI) 1099-1344(199901) 42:1<3::AID-JLCR160>3.0.CO;2-H 10.1002/(SICI)1099- 1344(199901)42:1<3::AID-JLCR160>3.0.CO;2-H 1:CAS:528:DyaK1MXpsVChsg%3D%3D
12. M Piert HJ Machulla M Picchio G Reischl S Ziegler P Kumar, et al. 2005 Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside J Nucl Med 46 106 113 15632040
13. D Sorger M Patt P Kumar LI Wiebe H Barthel A Seese, et al. 2003 [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors Nucl Med Biol 30 317 326 10.1016/S0969-8051(02) 00442-0 12745023 10.1016/S0969-8051(02)00442-0 1:CAS:528:DC%2BD3sXjs1Gjsrw%3D
14. AM Spence M Muzi KR Swanson F O'Sullivan JK Rockhill JG Rajendran, et al. 2008 Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival Clin Cancer Res 14 2623 2630 10.1158/1078-0432.CCR-07-4995 18451225 10.1158/1078-0432.CCR-07-4995 1:CAS:528:DC%2BD1cXlsV2qtr8%3D
15. M Bruehlmeier U Roelcke PA Schubiger SM Ametamey 2004 Assessment of hypoxia and perfusion in human brain tumors using PET with 18F- fluoromisonidazole and 15O-H2O J Nucl Med 45 1851 1859 15534054
16. LM Cher C Murone N Lawrentschuk S Ramdave A Papenfuss A Hannah, et al. 2006 Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies J Nucl Med 47 410 418 16513609 1:CAS:528: DC%2BD28Xlt1Kms7g%3D (Pubitemid 46768482)
17. RS Liu LS Chu YK Chu SH Yen SQ Liao SH Yeh 1999 Does h-oxidation occur in malignant neoplasm? A concurrent [C-11]acetate and [F-18]MISO study J Nucl Med 40 239 abstract
18. PE Valk CA Mathis MD Prados JC Gilbert TF Budinger 1992 Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole J Nucl Med 33 2133 2137 1334136 1:STN:280:DyaK3s%2FpsV2isQ%3D%3D
19. JM Brown P Workman 1980 Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole Radiat Res 82 171 190 10.2307/3575246 7367588 10.2307/3575246 1:CAS:528: DyaL3cXks1WjsLo%3D
20. SM Evans KW Jenkins WT Jenkins T Dilling KD Judy A Schrlau, et al. 2008 Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors Radiat Res 170 677 690 10.1667/RR1207.1 19138031 10.1667/RR1207.1 1:CAS:528:DC%2BD1cXhsVKgtLnP
21. SM Evans KD Judy I Dunphy WT Jenkins WT Hwang PT Nelson, et al. 2004 Hypoxia is important in the biology and aggression of human glial brain tumors Clin Cancer Res 10 8177 8184 10.1158/1078-0432.CCR-04-1081 15623592 10.1158/1078-0432.CCR-04-1081 1:CAS:528:DC%2BD2cXhtFGjsrjM (Pubitemid 40053376)
22. M Souvatzoglou AL Grosu B Roper BJ Krause R Beck G Reischl, et al. 2007 Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study Eur J Nucl Med Mol Imaging 34 1566 1575 10.1007/s00259-007-0424-3 17447061 10.1007/s00259-007-0424-3 1:STN:280:DC%2BD2srmtlWqsw%3D%3D (Pubitemid 47476913)
23. RJ Hicks D Rischin R Fisher D Binns AM Scott LJ Peters 2005 Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent Eur J Nucl Med Mol Imaging 32 1384 1391 10.1007/s00259-005-1880-2 16133382 10.1007/s00259-005-1880-2 (Pubitemid 41746841)
24. D Rischin RJ Hicks R Fisher D Binns J Corry S Porceddu, et al. 2006 Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2098 2104 16648512 10.1200/JCO.2005.05.2878 10.1200/JCO.2005.05.2878 (Pubitemid 46622121)
25. MH Cherk SS Foo AM Poon SR Knight C Murone AT Papenfuss, et al. 2006 Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET J Nucl Med 47 1921 1926 17138734 1:CAS:528:DC%2BD2sXksFKhtA%3D%3D (Pubitemid 47544979)
26. TZ Wong JL Lacy NA Petry TC Hawk TA Sporn MW Dewhirst, et al. 2008 PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator AJR Am J Roentgenol 190 427 432 10.2214/AJR.07.2876 18212229 10.2214/AJR.07.2876 (Pubitemid 351196614)
27. H Yasuda T Kaneta Y Takai K Nakayama R Iwata, et al. 2007 Tumor hypoxia imaging with [F-18] fluoronitroimidazole in non-small-cell lung cancer J Am Geriatr Soc 55 1142 1144 10.1111/j.1532-5415.2007.01218.x 17608896 10.1111/j.1532-5415.2007.01218.x (Pubitemid 47024613)
28. F Dehdashti PW Grigsby JS Lewis R Laforest BA Siegel MJ Welch 2008 Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) J Nucl Med 49 201 205 18199612 10.2967/jnumed.107.048520 1:CAS:528:DC%2BD1cXivVOltLw%3D (Pubitemid 351225657)